Strs Ohio Rain Therapeutics Inc. Transaction History

Strs Ohio

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$1.09 - $9.93 $109,109 - $993,993	100,100 New	100,100 $120,000
Q2 2022 Jul 25, 2022	SELL	$2.21 - $5.56 $3,757 - $9,452	-1,700 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$15.08 - $20.3 $25,636 - $34,510	1,700 New	1,700 $26,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.